PerkinElmer Introduces Immuno-Capture Technology for Mass Spectrometer Detection
Complete the form below to unlock access to ALL audio articles.
PerkinElmer Life and Analytical Sciences has introduced the Immuno-catch™ Kit, a next-generation immuno-capture technology optimized for mass spectrometer (MS) detection. Immuno-catch is a powerful alternative to slower, low-yield immunoprecipitation assays.
“With its simpler, standardized workflow and advanced chemistries, the Immuno-catch platform saves the researcher time, requires less sample volume, improves yield and allows greater reproducibility than with conventional immunoprecipitation applications,” says Richard Eglen, vice president and general manager of the Discovery and Research Reagents business of PerkinElmer Life and Analytical Sciences.
The kit consists of streptavidin-coated 96 well microplates and all the necessary buffers for binding and elution from the plate. The streptavidin coating procedure provides not only a high binding capacity for biotinylated capture agents, including antibodies, but also an extremely robust coating to allow easy elution of captured analytes. This provide a high-throughput, multiplex format for the enrichment of specific target proteins and peptides from complex biological samples (such as blood serum) and selective downstream analysis and detection using standard MS and gel technologies.
In addition to conventional immunoassays of intact proteins, the Immuno-catch Kit was designed to meet the unique requirements of investigators interested in the low molecular weight peptidomic environment. Researchers in the emerging discipline of peptidomics have high interest in peptide fragments as important markers of cellular signals and as potential markers of diagnostic information.
PerkinElmer is currently collaborating with Dr Lance Liotta and Dr Emanuel Petricoin, co-directors of the Center for Applied Proteomics and Molecular Medicine at George Mason University for the investigation of possible clinical utility of peptidomics and Immuno-catch.
According to Dr Liotta, “The Immuno-catch platform provides a critical component for our ongoing alliance with PerkinElmer to explore the peptidome, which we hypothesize to hold untapped and significant diagnostic potential."
